Depdc5 knockout rat: A novel model of mTORopathy

Neurobiology of Disease

Volumn 89, Issue , 2016, Pages 180-189

  Marsan, Elise ^a,b,c,d   Ishida, Saeko ^a,b,c,d   Schramm, Adrien ^a,b,c,d   Weckhuysen, Sarah ^a,b,c,d   Muraca, Giuseppe ^a,b,c,d   Lecas, Sarah ^a,b,c,d   Liang, Ning ^e,f   Treins, Caroline ^e,f   Pende, Mario ^e,f   Roussel, Delphine ^a,b,c,d   Le Van Quyen, Michel ^a,b,c,d   Mashimo, Tomoji ^g   Kaneko, Takehito ^h   Yamamoto, Takashi ⁱ   Sakuma, Tetsushi ⁱ   Mahon, Séverine ^a,b,c,d   Miles, Richard ^a,b,c,d   Leguern, Eric ^a,b,c,d,j   Charpier, Stéphane ^a,b,c,d   Baulac, Stéphanie ^a,b,c,d,j  

^a INSERM   (France)

^b CNRS   (France)

^c SORBONNE UNIVERSITÉ   (France)

^d INSTITUT DU CERVEAU ET DE LA MOELLE ÉPINIÈRE   (France)

^e INSTITUT NECKER ENFANTS MALADES   (France)

^f UNIVERSITÉ PARIS DESCARTES   (France)

^g OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^h KYOTO UNIVERSITY   (Japan)

ⁱ HIROSHIMA UNIVERSITY   (Japan)

^j PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

more..

Author keywords

DEPDC5; Familial focal epilepsy; Focal cortical dysplasia; Knockout; MTOR; Rapamycin

Indexed keywords

DEP DOMAIN CONTAINING 5; GUANOSINE TRIPHOSPHATASE ACTIVATING PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; RAPAMYCIN; S6 KINASE; S6 KINASE 1; UNCLASSIFIED DRUG; MECHANISTIC TARGET OF RAPAMYCIN COMPLEX 1; MULTIPROTEIN COMPLEX; REPRESSOR PROTEIN; TARGET OF RAPAMYCIN KINASE;

ADULT; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORTICAL DYSPLASIA; EMBRYO; ENZYME ACTIVATION; ENZYME INHIBITION; FEMALE; FIBROBLAST; HETEROZYGOTE; HOMOZYGOTE; HUMAN; IN VIVO STUDY; NERVE CELL EXCITABILITY; NONHUMAN; PHENOTYPE; PRENATAL PERIOD; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; RAT; SEIZURE; UPREGULATION; ABNORMALITIES; ANIMAL; ANTAGONISTS AND INHIBITORS; BRAIN CORTEX; DISEASE MODEL; DRUG EFFECTS; EMBRYO DEVELOPMENT; FISCHER 344 RAT; GENE INACTIVATION; GENETICS; GENOTYPE; METABOLISM; NERVE CELL; PATHOLOGY; PATHOPHYSIOLOGY; PHOSPHORYLATION; PHYSIOLOGY; SIGNAL TRANSDUCTION; TRANSGENIC ANIMAL; WISTAR RAT;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; CEREBRAL CORTEX; DISEASE MODELS, ANIMAL; EMBRYONIC DEVELOPMENT; FIBROBLASTS; GENE KNOCKOUT TECHNIQUES; GENOTYPE; MULTIPROTEIN COMPLEXES; NEURONS; PHOSPHORYLATION; RATS; RATS, INBRED F344; RATS, WISTAR; REPRESSOR PROTEINS; SIGNAL TRANSDUCTION; SIROLIMUS; TOR SERINE-THREONINE KINASES;

EID: 84958240587     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2016.02.010     Document Type: Article

References (51)

1. Abdijadid S., et al. Basic mechanisms of epileptogenesis in pediatric cortical dysplasia. CNS Neurosci. Ther. 2015, 21:92-103.
2. Acosta-Jaquez H.A., et al. Site-specific mTOR phosphorylation promotes mTORC1-mediated signaling and cell growth. Mol. Cell. Biol. 2009, 29:4308-4324.
3. Anderl S., et al. Therapeutic value of prenatal rapamycin treatment in a mouse brain model of tuberous sclerosis complex. Hum. Mol. Genet. 2011, 20:4597-4604.
4. Bar-Peled L., et al. A tumor suppressor complex with GAP activity for the Rag GTPases that signal amino acid sufficiency to mTORC1. Science 2013, 340:1100-1106.
5. Bateup H.S., et al. Excitatory/inhibitory synaptic imbalance leads to hippocampal hyperexcitability in mouse models of tuberous sclerosis. Neuron 2013, 78:510-522.
6. Baulac S., et al. Familial focal epilepsy with focal cortical dysplasia due to DEPDC5 mutations. Ann. Neurol. 2015, 77:675-683.
7. Baulac S., et al. A rat model for LGI1-related epilepsies. Hum. Mol. Genet. 2012, 21:3546-3557.
8. Baybis M., et al. mTOR cascade activation distinguishes tubers from focal cortical dysplasia. Ann. Neurol. 2004, 56:478-487.
9. Blumcke I., et al. The clinicopathologic spectrum of focal cortical dysplasias: a consensus classification proposed by an ad hoc task force of the ILAE diagnostic methods commission. Epilepsia 2011, 52:158-174.
10. D'Gama A.M., et al. Mammalian target of rapamycin pathway mutations cause hemimegalencephaly and focal cortical dysplasia. Ann. Neurol. 2015, 77:720-725.
11. Degenetais E., et al. Electrophysiological properties of pyramidal neurons in the rat prefrontal cortex: an in vivo intracellular recording study. Cereb. Cortex 2002, 12:1-16.
12. Dibbens L.M., et al. Mutations in DEPDC5 cause familial focal epilepsy with variable foci. Nat. Genet. 2013, 45:546-551.
13. Dutchak P.A., et al. Regulation of hematopoiesis and methionine homeostasis by mTORC1 inhibitor NPRL2. Cell Rep. 2015, 12:371-379.
14. Efeyan A., et al. RagA, but not RagB, is essential for embryonic development and adult mice. Dev. Cell 2014, 29:321-329.
15. Goto J., et al. Regulable neural progenitor-specific Tsc1 loss yields giant cells with organellar dysfunction in a model of tuberous sclerosis complex. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:E1070-E1079.
16. Ishida S., et al. Mutations of DEPDC5 cause autosomal dominant focal epilepsies. Nat. Genet. 2013, 45:552-555.
17. Ishida S., et al. Kcna1-mutant rats dominantly display myokymia, neuromyotonia and spontaneous epileptic seizures. Brain Res. 2012, 1435:154-166.
18. Kobayashi T., et al. A germ-line Tsc1 mutation causes tumor development and embryonic lethality that are similar, but not identical to, those caused by Tsc2 mutation in mice. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:8762-8767.
19. Kowalczyk M.S., et al. Nprl3 is required for normal development of the cardiovascular system. Mamm. Genome 2012, 23:404-415.
20. Lal D., et al. DEPDC5 mutations in genetic focal epilepsies of childhood. Ann. Neurol. 2014, 75:788-792.
21. Laplante M., Sabatini D.M. mTOR signaling in growth control and disease. Cell 2012, 149:274-293.
22. Lasarge C.L., Danzer S.C. Mechanisms regulating neuronal excitability and seizure development following mTOR pathway hyperactivation. Front. Mol. Neurosci. 2014, 7:18.
23. Liang N., et al. Regulation of YAP by mTOR and autophagy reveals a therapeutic target of tuberous sclerosis complex. J. Exp. Med. 2014, 211:2249-2263.
24. Lim K.C., Crino P.B. Focal malformations of cortical development: new vistas for molecular pathogenesis. Neuroscience 2013, 252:262-276.
25. Lozovaya N., et al. Selective suppression of excessive GluN2C expression rescues early epilepsy in a tuberous sclerosis murine model. Nat. Commun. 2014, 5:4563.
26. Ma A., et al. Tsc1 deficiency-mediated mTOR hyperactivation in vascular endothelial cells causes angiogenesis defects and embryonic lethality. Hum. Mol. Genet. 2014, 23:693-705.
27. Mahon S., Charpier S. Bidirectional plasticity of intrinsic excitability controls sensory inputs efficiency in layer 5 barrel cortex neurons in vivo. J Neurosci. 2012, 32:11377-11389.
28. Martin C., et al. A recurrent mutation in DEPDC5 predisposes to focal epilepsies in the French-Canadian population. Clin. Genet. 2014, 86:570-574.
29. Mashimo T., et al. Efficient gene targeting by TAL effector nucleases coinjected with exonucleases in zygotes. Sci Rep. 2013, 3:1253.
30. Mashimo T., et al. A missense mutation of the gene encoding voltage-dependent sodium channel (Nav1.1) confers susceptibility to febrile seizures in rats. J Neurosci. 2010, 30:5744-5753.
31. Meikle L., et al. Response of a neuronal model of tuberous sclerosis to mammalian target of rapamycin (mTOR) inhibitors: effects on mTORC1 and Akt signaling lead to improved survival and function. J Neurosci. 2008, 28:5422-5432.
32. Meikle L., et al. A mouse model of tuberous sclerosis: neuronal loss of Tsc1 causes dysplastic and ectopic neurons, reduced myelination, seizure activity, and limited survival. J Neurosci. 2007, 27:5546-5558.
33. Miyata H., et al. Insulin signaling pathways in cortical dysplasia and TSC-tubers: tissue microarray analysis. Ann. Neurol. 2004, 56:510-519.
34. Nunez A., et al. Electrophysiology of cat association cortical cells in vivo: intrinsic properties and synaptic responses. J. Neurophysiol. 1993, 70:418-430.
35. Onda H., et al. Tsc2(+/-) mice develop tumors in multiple sites that express gelsolin and are influenced by genetic background. J. Clin. Invest. 1999, 104:687-695.
36. Panchaud N., et al. Amino acid deprivation inhibits TORC1 through a GTPase-activating protein complex for the rag family GTPase Gtr1. Sci Signal. 2013, 6.
37. Paxinos G.W.,.C. The Rat Brain in Stereotaxic Coordinates 2005.
38. Paz J.T., et al. Multiple forms of activity-dependent intrinsic plasticity in layer V cortical neurones in vivo. J. Physiol. 2009, 587:3189-3205.
39. Picard F., et al. DEPDC5 mutations in families presenting as autosomal dominant nocturnal frontal lobe epilepsy. Neurology 2014, 82:2101-2106.
40. Polack P.O., Charpier S. Intracellular activity of cortical and thalamic neurones during high-voltage rhythmic spike discharge in Long-Evans rats in vivo. J. Physiol. 2006, 571:461-476.
41. Polack P.O., et al. Inactivation of the somatosensory cortex prevents paroxysmal oscillations in cortical and related thalamic neurons in a genetic model of absence epilepsy. Cereb. Cortex 2009, 19:2078-2091.
42. Rennebeck G., et al. Loss of function of the tuberous sclerosis 2 tumor suppressor gene results in embryonic lethality characterized by disrupted neuroepithelial growth and development. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:15629-15634.
43. Ricos M.G., et al. Mutations in the mTOR pathway regulators NPRL2 and NPRL3 cause focal epilepsy. Ann. Neurol. 2016, 79:120-131.
44. Sakuma T., et al. Repeating pattern of non-RVD variations in DNA-binding modules enhances TALEN activity. Sci Rep. 2013, 3:3379.
45. Scerri T., et al. Familial cortical dysplasia type IIA caused by a germline mutation in DEPDC5. Ann. Clin. Transl. Neurol. 2015, 2:575-580.
46. Scheffer I.E., et al. Mutations in mammalian target of rapamycin regulator DEPDC5 cause focal epilepsy with brain malformations. Ann. Neurol. 2014, 75:782-787.
47. Sim J.C., et al. Familial cortical dysplasia caused by mutation in the mTOR regulator NPRL3. Ann. Neurol. 2016, 79:132-137.
48. Tsai P.T., et al. Prenatal rapamycin results in early and late behavioral abnormalities in wildtype C57BL/6 mice. Behav. Genet. 2013, 43:51-59.
49. Way S.W., et al. The differential effects of prenatal and/or postnatal rapamycin on neurodevelopmental defects and cognition in a neuroglial mouse model of tuberous sclerosis complex. Hum. Mol. Genet. 2012, 21:3226-3236.
50. Wiegand G., et al. Everolimus in tuberous sclerosis patients with intractable epilepsy: a treatment option?. Eur. J. Paediatr. Neurol. 2013, 17:631-638.
51. Yang S.B., et al. Rapamycin ameliorates age-dependent obesity associated with increased mTOR signaling in hypothalamic POMC neurons. Neuron 2012, 75:425-436.